Moxonidine Viatris (Moxonidine)

• Moxonidine acts on central imidazoline I1 receptors to reduce sympathetic outflow, making it useful in hypertension management.
• Primary hypertension: reduces systemic blood pressure in patients with essential hypertension.
• Essential hypertension: helps achieve target blood pressure levels.
• Resistant hypertension: provides additional control when other antihypertensives are insufficient.

• Moxonidine selectively stimulates central imidazoline I1 receptors located in the rostral ventrolateral medulla. Activation of these receptors diminishes sympathetic nervous system activity, leading to reduced peripheral vascular resistance and lower cardiac output, which together lower arterial blood pressure. The drug’s action is independent of adrenergic receptors, providing an alternative pathway to traditional β‑blockers and ACE inhibitors. Consequently, it produces a modest decrease in heart rate without significant reflex tachycardia.

Moxonidine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects

• Dry mouth: persistent sensation of oral dryness that may affect swallowing.
• Drowsiness: mild sleepiness or fatigue that can occur during the day.
• Headache: mild to moderate head pain, often relieved with simple analgesics.
• Dizziness: feeling of light‑headedness, especially upon standing quickly.
• Nausea: upset stomach or urge to vomit, usually transient.
• Fatigue: persistent lack of energy that may interfere with daily activities.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting or syncope.
• Allergic reactions: rash, itching, swelling, or anaphylaxis in susceptible individuals.
• Liver enzyme elevation: increased ALT/AST levels indicating possible hepatic stress.
• Heart block: abnormal cardiac conduction that may require medical attention.

• Before initiating therapy, clinicians should consider several safety factors.
• Renal impairment: monitor kidney function and adjust therapy as needed.
• Hepatic dysfunction: use with caution; liver enzymes should be checked periodically.
• Elderly patients: increased sensitivity to blood pressure lowering; start at low dose.
• Concomitant antihypertensives: risk of additive hypotension; observe blood pressure closely.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines, requiring attention to combination therapy.

Major Interactions (Avoid)

• Combined use with other central antihypertensives (e.g., clonidine, guanfacine): may cause severe hypotension.
• Co‑administration with strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase plasma concentrations of moxonidine.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect.
• Diuretics: additive blood pressure lowering; monitor for orthostatic symptoms.
• Beta‑blockers: potential for enhanced hypotensive response; observe patient.